Company News: Dyax, Teva and Shire

Share this article:
Dyax received FDA approval for Kalbitor (ecallantide/DX-88) for treating acute attacks of hereditary angioedema (HAE), a rare, genetic disorder. Kalbitor is the first subcutaneous HAE treatment approved in the US, and analysts from Wolters Kluwer inThought forecast revenue of $600 million US, $850 million worldwide by 2016.

Teva and Shire settled a lawsuit over a supply contract for an authorized generic version of Shire's Adderall XR. No consideration was exchanged by the parties, Shire said. Shire has been supplying an authorized copy of the ADHD drug since April. Teva subsequently filed suit claiming Shire was in breach of contract due to supply issues. As the reason for the suit, Shire cited issues surrounding DEA restrictions placed on how much amphetamine it could ship, amphetamine being the product's active ingredient. After the lawsuit, DEA raised the 2009 quota for Shire, allowing it to supply Teva with additional amphetamine.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.